FRINK Linked Data Fragments server

Matches in Wikidata for { <http://www.wikidata.org/entity/Q37456300> ?p ?o ?g. }

• Q37456300 description "article científic" @default.
• Q37456300 description "article scientifique" @default.
• Q37456300 description "articolo scientifico" @default.
• Q37456300 description "artigo científico" @default.
• Q37456300 description "artículu científicu espublizáu en 2016" @default.
• Q37456300 description "bilimsel makale" @default.
• Q37456300 description "scientific article published on 25 April 2016" @default.
• Q37456300 description "vedecký článok" @default.
• Q37456300 description "vetenskaplig artikel" @default.
• Q37456300 description "videnskabelig artikel" @default.
• Q37456300 description "vědecký článek" @default.
• Q37456300 description "wetenschappelijk artikel" @default.
• Q37456300 description "wissenschaftlicher Artikel" @default.
• Q37456300 description "наукова стаття, опублікована у квітні 2016" @default.
• Q37456300 description "научни чланак" @default.
• Q37456300 description "مقالة علمية نشرت في 25 أبريل 2016" @default.
• Q37456300 name "A Multicenter, Randomized, Double-Blind, Placebo-Controlled Study to Evaluate the Efficacy and Safety of Treatment With Sirukumab (CNTO 136) in Patients With Active Lupus Nephritis" @default.
• Q37456300 name "A Multicenter, Randomized, Double-Blind, Placebo-Controlled Study to Evaluate the Efficacy and Safety of Treatment With Sirukumab (CNTO 136) in Patients With Active Lupus Nephritis" @default.
• Q37456300 name "A Multicenter, Randomized, Double-Blind, Placebo-Controlled Study to Evaluate the Efficacy and Safety of Treatment With Sirukumab (CNTO 136) in Patients With Active Lupus Nephritis" @default.
• Q37456300 type Item @default.
• Q37456300 label "A Multicenter, Randomized, Double-Blind, Placebo-Controlled Study to Evaluate the Efficacy and Safety of Treatment With Sirukumab (CNTO 136) in Patients With Active Lupus Nephritis" @default.
• Q37456300 label "A Multicenter, Randomized, Double-Blind, Placebo-Controlled Study to Evaluate the Efficacy and Safety of Treatment With Sirukumab (CNTO 136) in Patients With Active Lupus Nephritis" @default.
• Q37456300 label "A Multicenter, Randomized, Double-Blind, Placebo-Controlled Study to Evaluate the Efficacy and Safety of Treatment With Sirukumab (CNTO 136) in Patients With Active Lupus Nephritis" @default.
• Q37456300 prefLabel "A Multicenter, Randomized, Double-Blind, Placebo-Controlled Study to Evaluate the Efficacy and Safety of Treatment With Sirukumab (CNTO 136) in Patients With Active Lupus Nephritis" @default.
• Q37456300 prefLabel "A Multicenter, Randomized, Double-Blind, Placebo-Controlled Study to Evaluate the Efficacy and Safety of Treatment With Sirukumab (CNTO 136) in Patients With Active Lupus Nephritis" @default.
• Q37456300 prefLabel "A Multicenter, Randomized, Double-Blind, Placebo-Controlled Study to Evaluate the Efficacy and Safety of Treatment With Sirukumab (CNTO 136) in Patients With Active Lupus Nephritis" @default.
• Q37456300 P1433 Q37456300-6394ECCB-CB3F-410F-86D8-5C9323931E3E @default.
• Q37456300 P1476 Q37456300-0ABAD66B-781B-4481-99FD-2298BCDC624A @default.
• Q37456300 P2093 Q37456300-297BD180-D0B8-4891-BDC5-15BD7BEA4861 @default.
• Q37456300 P2093 Q37456300-362B64F4-2C7C-42EE-82D3-14D11AB6C047 @default.
• Q37456300 P2093 Q37456300-56F36915-9CCF-4E41-9271-9E83F4357492 @default.
• Q37456300 P2093 Q37456300-6D17DF27-473B-4501-A575-C6C7F4031D70 @default.
• Q37456300 P2093 Q37456300-F90CA5A7-BF0B-44A3-B58F-B51B148E3C06 @default.
• Q37456300 P2860 Q37456300-0685EBB4-2C0D-4D6C-8A15-55664DAA6208 @default.
• Q37456300 P2860 Q37456300-080395F8-73DC-4EE2-8FA5-FEBB8CC009F6 @default.
• Q37456300 P2860 Q37456300-0BD2D686-92B0-442E-85E1-D357EBA05273 @default.
• Q37456300 P2860 Q37456300-134681CB-D1FE-4C90-B0BD-9FB3C8A14439 @default.
• Q37456300 P2860 Q37456300-2689EAA5-B1E2-4FD3-95D5-131191BECD30 @default.
• Q37456300 P2860 Q37456300-281390FC-9200-4F7D-AEAF-E764F3E1C2B3 @default.
• Q37456300 P2860 Q37456300-2C1C6ADA-8121-4347-8DB9-F9DF79C786D4 @default.
• Q37456300 P2860 Q37456300-2F9F38AB-E6A9-40AF-BC1C-D363A303D3B8 @default.
• Q37456300 P2860 Q37456300-482C1757-A904-430E-87A1-612397B1799C @default.
• Q37456300 P2860 Q37456300-6AEE629B-3ABE-4ACC-A536-0147DB5FDD9A @default.
• Q37456300 P2860 Q37456300-6CF99EE0-FE99-44EB-9761-CA84F29E8149 @default.
• Q37456300 P2860 Q37456300-77FCECE4-384D-4B1F-8185-201696EFEDA3 @default.
• Q37456300 P2860 Q37456300-782BA3D4-D5EF-4A1C-A74B-79283831761A @default.
• Q37456300 P2860 Q37456300-8325F105-E80E-46B3-980B-74E1AF1BF32B @default.
• Q37456300 P2860 Q37456300-925CA944-0C11-4ED6-A56A-78EB925F0663 @default.
• Q37456300 P2860 Q37456300-96D88BC8-FC4B-4749-931B-820D44B2C374 @default.
• Q37456300 P2860 Q37456300-9E0EDF68-2A12-4488-B66C-A3A125A9A92F @default.
• Q37456300 P2860 Q37456300-A545D80B-6975-4DC8-B15F-3501B5C71E45 @default.
• Q37456300 P2860 Q37456300-A99AA404-5283-464A-94DA-A7FA3894CF87 @default.
• Q37456300 P2860 Q37456300-AD1EB105-955C-40A1-80B2-8DE6C0A58D6A @default.
• Q37456300 P2860 Q37456300-B918B98D-CBED-4D93-B035-82D7A24B5621 @default.
• Q37456300 P2860 Q37456300-C440730E-5EDE-4802-843A-5EDB749CA630 @default.
• Q37456300 P2860 Q37456300-CBE7671D-41B7-4EF1-86FE-06EB94EEF3EC @default.
• Q37456300 P2860 Q37456300-CEFF292C-69C8-4B1B-9187-EE72C0B44E70 @default.
• Q37456300 P2860 Q37456300-CF1480DC-433A-4716-AAE4-C86B0846487C @default.
• Q37456300 P2860 Q37456300-D1131908-6FB7-4794-995B-8DCE15282950 @default.
• Q37456300 P2860 Q37456300-D6C2746C-7EF5-4D30-B74B-8EDE073824D0 @default.
• Q37456300 P2860 Q37456300-D6F67EBC-A4EF-4D1A-92E3-6B35343028A6 @default.
• Q37456300 P2860 Q37456300-DDB6EBBF-1AC4-4D6C-87AB-32F415C20A1E @default.
• Q37456300 P2860 Q37456300-EA9EECE8-5368-473A-96D5-FD921B769545 @default.
• Q37456300 P2860 Q37456300-EB39F4A8-EC12-4B52-A60A-B46192635079 @default.
• Q37456300 P2860 Q37456300-F2C387AB-1B11-48F1-928A-FFE4B693E7E8 @default.
• Q37456300 P2860 Q37456300-FAE9F7F6-9F8E-4706-88A2-617F6CD0D7CE @default.
• Q37456300 P2860 Q37456300-FF7ABF29-E3B4-411D-8A4A-4CA2676267F7 @default.
• Q37456300 P304 Q37456300-721D93CF-8B9B-434F-8274-23E91A3BAC9C @default.
• Q37456300 P31 Q37456300-508FE9D3-8BE0-4564-ACA9-03ED8D58879A @default.
• Q37456300 P356 Q37456300-514CD972-F36E-42AD-822F-3D7094A5AEE6 @default.
• Q37456300 P433 Q37456300-20D6EE78-B60A-4053-8659-5EC4CF668322 @default.
• Q37456300 P478 Q37456300-EDA836C1-A1AA-49B3-969F-87E2298458CD @default.
• Q37456300 P50 Q37456300-4909A49B-EAAE-4167-A943-1B24F43242C2 @default.
• Q37456300 P50 Q37456300-82731784-C580-4EC9-B0BD-E279DBCBE73C @default.
• Q37456300 P50 Q37456300-A3CB4549-5840-4BE6-AA4E-C67DEEC03585 @default.
• Q37456300 P577 Q37456300-2F4D9602-8895-435A-808D-5BC896183844 @default.
• Q37456300 P698 Q37456300-EA0B7695-BF11-4D4E-87F0-DD08D1165256 @default.
• Q37456300 P921 Q37456300-09C5499A-AAB0-4002-BCCB-136825F12A4A @default.
• Q37456300 P921 Q37456300-C04B75B3-6CD9-4B93-9946-44AB567177AD @default.
• Q37456300 P932 Q37456300-5CF9B388-E9E4-49A8-9ABF-BBCA5F0167BD @default.
• Q37456300 P356 ART.39722 @default.
• Q37456300 P698 27110697 @default.
• Q37456300 P1433 Q4797636 @default.
• Q37456300 P1476 "A Multicenter, Randomized, Double-Blind, Placebo-Controlled Study to Evaluate the Efficacy and Safety of Treatment With Sirukumab (CNTO 136) in Patients With Active Lupus Nephritis" @default.
• Q37456300 P2093 "Benjamin Hsu" @default.
• Q37456300 P2093 "Carrie Wagner" @default.
• Q37456300 P2093 "Robert Gordon" @default.
• Q37456300 P2093 "Stanley Belkowski" @default.
• Q37456300 P2093 "Yanli Zhuang" @default.
• Q37456300 P2860 Q26995082 @default.
• Q37456300 P2860 Q26998390 @default.
• Q37456300 P2860 Q29547225 @default.
• Q37456300 P2860 Q29614889 @default.
• Q37456300 P2860 Q33329033 @default.
• Q37456300 P2860 Q33409403 @default.
• Q37456300 P2860 Q34092469 @default.
• Q37456300 P2860 Q34293066 @default.
• Q37456300 P2860 Q34978377 @default.
• Q37456300 P2860 Q35183631 @default.
• Q37456300 P2860 Q38170198 @default.

• next